Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation (Q40669830)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 August 2015

Language	Label	Description	Also known as
English	Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation	scientific article published on 2 August 2015

Statements

scholarly article

1 reference

Europe PubMed Central

22 September 2017

Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation (English)

1 reference

Europe PubMed Central

22 September 2017

Jakob R. Passweg

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233683%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

A Tschan-Plessl

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233683%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

J P Halter

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233683%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

D Heim

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233683%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

M Medinger

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233683%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

S Gerull

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233683%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

publication date

2 August 2015

1 reference

Europe PubMed Central

22 September 2017

Annals of Hematology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233683%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

94

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233683%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233683%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1899-1905

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233683%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Therapeutic advances in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

The role of FLT3 in haematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

Defining the intensity of conditioning regimens: working definitions

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2461-5

21 January 2018

Identifiers

10.1007/S00277-015-2461-5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233683%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26233683%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40669830&oldid=1904422935"